Literature DB >> 25610742

Targeting Galectin-1 in pancreatic cancer: immune surveillance on guard.

Neus Martínez-Bosch1, Pilar Navarro1.   

Abstract

The tumor microenviroment and immune barrier are known to modulate malignant disease progression. We have recently identified Galectin-1 as a key player in a novel stromal regulatory reaction driving immune evasion in pancreatic tumors in vivo. These results suggest that Galectin-1 inhibition represents a potential therapeutic strategy for one of the most deadly types of cancer.

Entities:  

Keywords:  Galectin-1; immune evasion; immunosurveillance; pancreatic cancer; stroma; tumor microenvironment

Year:  2014        PMID： 25610742      PMCID： PMC4292238          DOI： 10.4161/21624011.2014.952201

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  The immune network in pancreatic cancer development and progression.

Authors:  S M Wörmann; K N Diakopoulos; M Lesina; H Algül
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

2.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 3.  Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment.

Authors:  Koichi Ito; Kimberley Stannard; Elwyn Gabutero; Amanda M Clark; Shi-Yong Neo; Selda Onturk; Helen Blanchard; Stephen J Ralph
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

Review 4.  Unraveling galectin-1 as a novel therapeutic target for cancer.

Authors:  Lucile Astorgues-Xerri; Maria E Riveiro; Annemilaï Tijeras-Raballand; Maria Serova; Cindy Neuzillet; Sébastien Albert; Eric Raymond; Sandrine Faivre
Journal:  Cancer Treat Rev       Date:  2013-08-01       Impact factor: 12.111

Review 5.  Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.

Authors:  K Sideras; H Braat; J Kwekkeboom; C H van Eijck; M P Peppelenbosch; S Sleijfer; M Bruno
Journal:  Cancer Treat Rev       Date:  2013-11-23       Impact factor: 12.111

6.  Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma.

Authors:  Ru Chen; Sheng Pan; Niki A Ottenhof; Roeland F de Wilde; Christopher L Wolfgang; Zhaoli Lane; Jane Post; Mary P Bronner; Jürgen K Willmann; Anirban Maitra; Teresa A Brentnall
Journal:  Cancer Biol Ther       Date:  2012-08-01       Impact factor: 4.742

7.  High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer.

Authors:  Dong Tang; Zhongxu Yuan; Xiaofeng Xue; Zipeng Lu; Ye Zhang; Hui Wang; Minyong Chen; Yong An; Jishu Wei; Yi Zhu; Yi Miao; Kuirong Jiang
Journal:  Int J Cancer       Date:  2011-11-28       Impact factor: 7.396

8.  Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer.

Authors:  Oriol Roda; Elena Ortiz-Zapater; Neus Martínez-Bosch; Ricardo Gutiérrez-Gallego; Miquel Vila-Perelló; Coral Ampurdanés; Hans-Joachim Gabius; Sabine André; David Andreu; Francisco X Real; Pilar Navarro
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

9.  Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.

Authors:  Neus Martínez-Bosch; Maite G Fernández-Barrena; Mireia Moreno; Elena Ortiz-Zapater; Jessica Munné-Collado; Mar Iglesias; Sabine André; Hans-Joachim Gabius; Rosa F Hwang; Françoise Poirier; Carolina Navas; Carmen Guerra; Martin E Fernández-Zapico; Pilar Navarro
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

10.  A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation.

Authors:  Mylinh La; Thong V Cao; Graziela Cerchiaro; Kathya Chilton; Jun Hirabayashi; Ken-Ichi Kasai; Sonia M Oliani; Yuti Chernajovsky; Mauro Perretti
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307
  10 in total
  7 in total

Review 1.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

2.  Toward a new and noninvasive diagnostic method of papillary thyroid cancer by using peptide vectorized contrast agents targeted to galectin-1.

Authors:  Deborah Fanfone; Nadège Despretz; Dimitri Stanicki; Jenifer Rubio-Magnieto; Mathieu Fossépré; Mathieu Surin; Sandrine Rorive; Isabelle Salmon; Luce Vander Elst; Sophie Laurent; Robert N Muller; Sven Saussez; Carmen Burtea
Journal:  Med Oncol       Date:  2017-10-06       Impact factor: 3.064

3.  Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.

Authors:  Sophie Dobiasch; Szilard Szanyi; Aleko Kjaev; Jens Werner; Albert Strauss; Christian Weis; Lars Grenacher; Katya Kapilov-Buchman; Liron-Limor Israel; Jean-Paul Lellouche; Erica Locatelli; Mauro Comes Franchini; Jennifer Vandooren; Ghislain Opdenakker; Klaus Felix
Journal:  J Nanobiotechnology       Date:  2016-12-19       Impact factor: 10.435

Review 4.  Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.

Authors:  Neus Martinez-Bosch; Judith Vinaixa; Pilar Navarro
Journal:  Cancers (Basel)       Date:  2018-01-03       Impact factor: 6.639

Review 5.  Proteome alterations in pancreatic ductal adenocarcinoma.

Authors:  Sheng Pan; Teresa A Brentnall; Ru Chen
Journal:  Cancer Lett       Date:  2019-11-14       Impact factor: 9.756

6.  Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker.

Authors:  Neus Martinez-Bosch; Luis E Barranco; Carlos A Orozco; Mireia Moreno; Laura Visa; Mar Iglesias; Lucy Oldfield; John P Neoptolemos; William Greenhalf; Julie Earl; Alfredo Carrato; Eithne Costello; Pilar Navarro
Journal:  Oncotarget       Date:  2018-08-31

7.  Pancreatic Cancer detection via Galectin-1-targeted Thermoacoustic Imaging: validation in an in vivo heterozygosity model.

Authors:  Huan Qin; Baohua Qin; Chang Yuan; Qun Chen; Da Xing
Journal:  Theranostics       Date:  2020-07-14       Impact factor: 11.556
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.